ARQ 621 |
An Eg5 inhibitor; reduces tumor growth in a MIA PaCa-2 pancreatic cancer m… |
1 mg |
34329-1 |
More Info
|
ARQ 621 |
An Eg5 inhibitor; reduces tumor growth in a MIA PaCa-2 pancreatic cancer m… |
10 mg |
34329-10 |
More Info
|
ARQ 621 |
An Eg5 inhibitor; reduces tumor growth in a MIA PaCa-2 pancreatic cancer m… |
25 mg |
34329-25 |
More Info
|
ARQ 621 |
An Eg5 inhibitor; reduces tumor growth in a MIA PaCa-2 pancreatic cancer m… |
5 mg |
34329-5 |
More Info
|
ARQ-092 |
A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5… |
1 mg |
21388-1 |
More Info
|
ARQ-092 |
A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5… |
10 mg |
21388-10 |
More Info
|
ARQ-092 |
A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5… |
25 mg |
21388-25 |
More Info
|
ARQ-092 |
A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5… |
5 mg |
21388-5 |
More Info
|
ARQ 531 |
A BTK inhibitor (IC50 = 0.85 nM); reduces the viability of, and inhibits B… |
1 mg |
30165-1 |
More Info
|
ARQ 531 |
A BTK inhibitor (IC50 = 0.85 nM); reduces the viability of, and inhibits B… |
10 mg |
30165-10 |
More Info
|
ARQ 531 |
A BTK inhibitor (IC50 = 0.85 nM); reduces the viability of, and inhibits B… |
25 mg |
30165-25 |
More Info
|
ARQ 531 |
A BTK inhibitor (IC50 = 0.85 nM); reduces the viability of, and inhibits B… |
5 mg |
30165-5 |
More Info
|
(6aR,9R)-11-hydroxy-Δ10-THC |
An analytical reference standard that is structurally similar to known phy… |
1 mg |
38231-1 |
More Info
|
(6aR,9R)-11-hydroxy-Δ10-THC |
An analytical reference standard that is structurally similar to known phy… |
100 µg |
38231-100 |
More Info
|
(6aR, 9R)-11-hydroxy-Δ10-THC (exempt preparation) |
An analytical reference standard that is structurally similar to known phy… |
100 µg |
41299-100 |
More Info
|
(6aR,9R)-11-nor-9-carboxy-Δ10-THC |
An analytical reference standard that is structurally similar to known phy… |
1 mg |
38235-1 |
More Info
|
(6aR,9R)-11-nor-9-carboxy-Δ10-THC |
An analytical reference standard that is structurally similar to known phy… |
500 µg |
38235-500 |
More Info
|
ARRY-382 |
A CSF1R inhibitor (IC50 = 9 nM); selective for CSF1R over PDGFR, c-Kit, an… |
1 mg |
38796-1 |
More Info
|
ARRY-382 |
A CSF1R inhibitor (IC50 = 9 nM); selective for CSF1R over PDGFR, c-Kit, an… |
10 mg |
38796-10 |
More Info
|
ARRY-382 |
A CSF1R inhibitor (IC50 = 9 nM); selective for CSF1R over PDGFR, c-Kit, an… |
5 mg |
38796-5 |
More Info
|
ARRY-520 |
A potent Eg5 inhibitor (IC50 = 6 nM); selective for Eg5 over a panel of 8… |
1 mg |
21883-1 |
More Info
|
ARRY-520 |
A potent Eg5 inhibitor (IC50 = 6 nM); selective for Eg5 over a panel of 8… |
10 mg |
21883-10 |
More Info
|
ARRY-520 |
A potent Eg5 inhibitor (IC50 = 6 nM); selective for Eg5 over a panel of 8… |
25 mg |
21883-25 |
More Info
|
ARRY-520 |
A potent Eg5 inhibitor (IC50 = 6 nM); selective for Eg5 over a panel of 8… |
5 mg |
21883-5 |
More Info
|
Arry-380 analog |
An inhibitor of EGFR |
1 mg |
24186-1 |
More Info
|
Arry-380 analog |
An inhibitor of EGFR |
10 mg |
24186-10 |
More Info
|
Arry-380 analog |
An inhibitor of EGFR |
25 mg |
24186-25 |
More Info
|
Arry-380 analog |
An inhibitor of EGFR |
5 mg |
24186-5 |
More Info
|
ARS1620 |
A covalent inhibitor of K-RASG12C (IC50 = G12C (IC50s = 150 nM) over vario… |
1 mg |
27915-1 |
More Info
|
ARS1620 |
A covalent inhibitor of K-RASG12C (IC50 = G12C (IC50s = 150 nM) over vario… |
5 mg |
27915-5 |
More Info
|
ARS853 |
An inhibitor of K-RASG12C; decreases the level of active GTP-bound K-RAS b… |
1 mg |
19137-1 |
More Info
|
ARS853 |
An inhibitor of K-RASG12C; decreases the level of active GTP-bound K-RAS b… |
10 mg |
19137-10 |
More Info
|
ARS853 |
An inhibitor of K-RASG12C; decreases the level of active GTP-bound K-RAS b… |
5 mg |
19137-5 |
More Info
|
ARS853 |
An inhibitor of K-RASG12C; decreases the level of active GTP-bound K-RAS b… |
500 µg |
19137-500 |
More Info
|
Arsenobetaine |
An organoarsenical and compatible solute; protective against B. subtilis c… |
50 mg |
34515-50 |
More Info
|
Arteannuin B |
A precursor of artemisinin with diverse biological activities; active agai… |
1 mg |
33852-1 |
More Info
|
Arteannuin B |
A precursor of artemisinin with diverse biological activities; active agai… |
10 mg |
33852-10 |
More Info
|
Arteannuin B |
A precursor of artemisinin with diverse biological activities; active agai… |
25 mg |
33852-25 |
More Info
|
Arteannuin B |
A precursor of artemisinin with diverse biological activities; active agai… |
5 mg |
33852-5 |
More Info
|
Arteether |
An antimalarial compound and derivative of artemisinin; inhibits P. falcip… |
10 mg |
11814-10 |
More Info
|
Arteether |
An antimalarial compound and derivative of artemisinin; inhibits P. falcip… |
25 mg |
11814-25 |
More Info
|
Arteether |
An antimalarial compound and derivative of artemisinin; inhibits P. falcip… |
5 mg |
11814-5 |
More Info
|
Arteether |
An antimalarial compound and derivative of artemisinin; inhibits P. falcip… |
50 mg |
11814-50 |
More Info
|
Artefenomel |
An antimalarial agent; active against 3D7, Cam3.II, and Cam3.II_rev P. fal… |
1 mg |
30677-1 |
More Info
|
Artefenomel |
An antimalarial agent; active against 3D7, Cam3.II, and Cam3.II_rev P. fal… |
5 mg |
30677-5 |
More Info
|
Artemether |
An antiparasitic compound and a derivative of artemisinin; induces mortali… |
1 g |
11815-1 |
More Info
|
Artemether |
An antiparasitic compound and a derivative of artemisinin; induces mortali… |
500 mg |
11815-500 |
More Info
|
Artemether-d3 |
An internal standard for the quantification of artemether by GC- or LC-MS |
1 mg |
28517-1 |
More Info
|
Artemether-d3 |
An internal standard for the quantification of artemether by GC- or LC-MS |
10 mg |
28517-10 |
More Info
|
Artemether-d3 |
An internal standard for the quantification of artemether by GC- or LC-MS |
5 mg |
28517-5 |
More Info
|